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Vector Systems for Nucleic Acid Delivery
• Ability to deliver a diverse range of genetic material 
 RNAi, shRNA, oligos, pDNA
• Chemistry allows for modification/targeting 
 specificity, hydrophobic moieties, pegylation
• High transfection efficiency  PEI based system??
• Minimal toxicity due to direct exposure or immune 









































Glutathione Reduction Inside the Cell
• Intracellular [GSH] is 50 - 1000 fold higher than extracellular space
• Bacterial toxins cholera and diphtheria take advantage of redox
potential during translocation into host cells
• Disulfide bioconjugation has been popular in a variety of cellular 
drug delivery systems  enhanced cytosolic delivery, improved 
pharmacokinetics, and increased stability
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Reducible Poly(amido ethylenimine)s
(SS-PAEI)s
• Polymers synthesized at 50º C 
under Argon and purified using 
MWCO 1000 high pressure 
dialysis system
• 3 new polymers synthesized 
and characterized via 1H-NMR, 






























































Polymer Reaction Mn (kDa) Mw (kDa) Mw/Mn Titration % Protonated Degree of
Time (mol HCl) Nitrogens Branching
poly(EDA/CBA) 48 h 1.6 2.0 1.26 8.2 21.9 0.37
poly(DETA/CBA) 18 h 3.3 4.8 1.47 5.0 10.1 0.72
poly(TETA/CBA) 16 h 2.3 3.4 1.45 8.5 14.4 0.64
bPEI 25k -- 6.5 9.5 1.47 18.8 13.5 --
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• Buffering capacity seems to be 
correlated with degree of branching
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• Form stable nanoparticles
< 200  nm
• There does not seem to be 
any interaction with pDNA
when polymer is reduced
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• Transfections produced similar 
results for fibroblasts (NIH3T3), 
endothelial cells (BAEC) and 
smooth muscle cells (A7R5)
n=3±SE
n=4±SEM
• Luc analysis done 48 hr 
post transfection
• MTT assay performed 24 
hr post transfection
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Serum Interaction and DNA Protection
0   30   60   90  120 0   30   60   90  120
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pDNA EDA/CBA
DETA/CBA TETA/CBA
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n=3±SEM, *p<0.05
• PEI has significantly higher amount of 
serum interactions
• Protect against DNAse degradation 
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Confocal Microscopy on EMA Distribution
• Ethidium monoazide (EMA) labeled pDNA
was used for transfections on NIH 3T3 
• Reducible polymer displays more dispersed 
fluorescence after 6 hr compared to bPEI
• Earlier time points did not reveal such a 
difference in fluorescence
 Due to reducible disulfide bonds?
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Effect on the Presence of GSH Inhibitor 
DL-Buthionine Sulfoxamine (BSO)• BSO decreases intracellular GSH
• Gene expression dependent upon GSH levels






• What about siRNA delivery??
• 200 bp vs 5 kbp
• Targeting the cytoplasm instead the nucleus






























• New class of biodegradable polymer synthesized and characterized
• Polymers interact with pDNA to form stable complexes able to 
transfect pDNA
• Polymers show higher expression than control at lower toxicity
• Reducible polymer mediated transfection is dependent upon GSH
14Biomaterials (2006) in submission.
Gel Electrophoresis of Polymer/siRNA
• Gel electrophoresis shows similar complexing w/w
• Presence of a reducing agent prevents interactions 
at all w/w looked at
PEI    0   .25  .75  1.5     3     6   12
Complexing w/DNA
DTT: disulfide reducing agent
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FACS Analysis of FITC-siRNA Delivery
• FITC labeled siRNA showed similar levels of cellular localization for 
both polymer carriers looked at in human prostate carcinoma cells 
(PC-3)
• Polymer mediated delivery showed higher localization than naked
delivery  
16Biomaterials (2006) in submission.
VEGF Suppression In Vitro
• RNAi-induced expression of VEGF expression on PC-3 cells 
• TETA-CBA mediated delivery showed statistically higher reduction 
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Effect on the Presence of BSO
n=3±SD, *p< 0.01
• Effect of BSO on the siRNA-mediated expression of VEGF on PC-3 cells 
for PEI and TETA-CBA at 1.2:1 and 6:1 w/w respectvely
• Delivery of reducible polymer mediated siRNA again seems GSH 
dependent
18Biomaterials (2006) in submission.
Confocal Microscopy
• FITC labeled siRNA was used for 
delivery to PC-3 cells 
• Reducible polymer mediated 
delivery displays more dispersed 
fluorescence after 5 hr compared to 
bPEI
• Lower magnification demonstrates 
































• SS-PAEIs are a new type of biodegradable 
carrier that can be used for efficient 
intracellular delivery of a broad range of
nucleic acids
• SS-PAEIs successfully interact with siRNA long enough to deliver a 
significant effect in vitro
• ~90% knockdown of VEGF was seen for siRNA delivery compared to 
only ~65% for a PEI control 
• Experiments showed a dependence upon GSH inside the cell
• Confocal microscopy experiments detailed the difference in delivery 
between reducible and nonreducible cationic polymers
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